Article Text
Statistics from Altmetric.com
When weighing up which inhaler to prescribe, a doctor may prioritise a patient’s preferences over the expected harms from the associated carbon emissions. Parker argues that this is wrong.1 Doctors have a pro-tanto duty to switch from a high-carbon metered-dose inhaler (MDI) to a low-carbon dry-powdered inhaler (DPI)—even though this provides no direct patient benefit—unless switching would undermine trust or significantly worsen a patient’s health. He goes on to state that even if DPIs are more expensive for the National Health Service (NHS) then this is justified so long as it does not ‘significantly threaten’ the NHS’ ability to protect and promote health. This may appear to be a radical proposal, challenging the ethical principles of autonomy, health entitlements and justly distributed resources. However, we will claim that it is only radical in so far as one perceives (A) patient autonomy and healthcare entitlements as existing within a vacuum, unrelated to other foundational ethics concerns and (B) the health consequences of a given healthcare budget are limited solely to the designated recipients rather than all affected parties. Here, we test the claim that our responsibility for promoting patient autonomy …
Footnotes
Twitter @abhopal_1
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Barriers to green inhaler prescribing: ethical issues in environmentally sustainable clinical practice
- Improving the environmental sustainability of paediatric care
- Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England
- Carbon footprint of hospital laundry: a life-cycle assessment
- Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study
- Before/after intervention study to determine impact on life-cycle carbon footprint of converting from single-use to reusable sharps containers in 40 UK NHS trusts
- What would an environmentally sustainable reproductive technology industry look like?
- Carbon footprint impact of the choice of inhalers for asthma and COPD
- Call for sustainable food systems including (medical) nutrition for hospitalised children and their families
- Carbon footprinting for the gastroenterologist